Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
GLYCAR T cells
i
Other names:
GPC3-CAR T cell therapy, GLYCAR T cells, Glypican 3-specific Chimeric Antigen Receptor T cells
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Baylor College of Medicine
Drug class:
GPC-3-targeted CAR-T immunotherapy
Related drugs:
‹
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
B010-A (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
IM83 (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
CT017 (1)
ADI-002 (0)
AGAR T cells (0)
AZD7003 (0)
B010-A (0)
BOXR1030 (0)
CT011 (0)
CT0180 (0)
CT0181 (0)
EU307 (0)
GAP T cells (0)
GPC3-CAR and IL15 plus IL21 (0)
GPC3-CAR-T Cells (0)
GPC3-CAR-T cells (0)
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells (0)
IM83 (0)
LB2101 (0)
Mesothelin/GPC3/GUCY2C-CAR-T (0)
NIB102 (0)
Ori-C101 (0)
TAI-GPC3-CART cells (0)
›
Associations
News
Trials
Filter by
Latest
almost2years
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
P1, N=9, Completed, Baylor College of Medicine | Active, not recruiting --> Completed | Trial completion date: Oct 2036 --> Jan 2023
almost 2 years ago
Trial completion • Trial completion date
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • GLYCAR T cells
over2years
Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=14 --> 9
over 2 years ago
Enrollment closed • Enrollment change
|
GPC3 (Glypican 3)
|
GPC3 positive
|
cyclophosphamide • fludarabine IV • GLYCAR T cells
over4years
A Phase 1 Clinical Trial Using Armored GPC3-Car T Cells for Children with Relapsed/ Refractory Liver Tumors (ASGCT 2020)
The initial results from this clinical trial show that GPC3-CAR T cells are well tolerated and have anti-tumor activity in children with liver tumors.
over 4 years ago
Clinical • P1 data • CAR T-Cell Therapy • IO biomarker
|
CD8 (cluster of differentiation 8) • GPC3 (Glypican 3)
|
GLYCAR T cells
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login